caa a22 4500 445803355 CHVBK 20180317145148.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s10337-011-2111-6 doi (NATIONALLICENCE)springer-10.1007/s10337-011-2111-6 HPLC-DAD Analysis of Hydrochlorothiazide and Irbesartan in Hypertensive Patients on Fixed-Dose Combination Therapy [Elektronische Daten] [François Coudoré, Laurent Harvard, Sandrine Lefeuvre, Eliane Billaud, Philippe Beaune, Guillaume Bobrie, Michel Azizi, Patrice Prognon, Stéphane Laurent] Hydrochlorothiazide (HCTZ) and the angiotensin II type 1 receptor antagonist (ARB) irbesartan (IRBE) are well-known antihypertensive drugs, frequently administered as a low-dose combination in a single pill. In this work, a simple, sensitive, and selective high-performance liquid chromatographic (HPLC) method with diode-array detection was developed for simultaneous determination of HCTZ and IRBE levels in the plasma of hypertensive patients given a fixed combination of 12.5mg HCTZ and 300mg IRBE. Compounds were extracted from acidified plasma samples with 3mL ethyl acetate, and eluted at 6 and 19min from a C4 column by elution with an acetonitrile-phosphate buffer (pH3.6) mobile-phase gradient at a flow rate of 1mLmin−1. The assay was linear over the ranges 2.5-500 and 20-4,000ngmL−1 for HCTZ and IRBE, respectively. Overall intra-assay and inter-assay variation were within acceptance limits. Limits of quantification were 2.5 and 20 ngmL−1 for HCTZ and IRBE, respectively. Plasma samples remained stable for 12h at room temperature, through three thaw-freeze cycles, and for 2 and 7months at −20°C. In hypertensive patients, residual concentrations were 22.3±6.0 and 241.8±39.0ngmL−1 for HCTZ and IRBE, respectively. There was no interference from other co-administered drugs. Despite the different physicochemical properties of HCTZ and IRBE, our method enables accurate measurement of both drugs for assessment of compliance by patients treated by fixed-dose combination therapy with HCTZ-IRBE. Springer-Verlag, 2011 HPLC-DAD nationallicence Hydrochlorothiazide nationallicence Irbesartan nationallicence Human plasma nationallicence Coudoré François Pharmacology Department, 75908, Paris, France aut Harvard Laurent Pharmacy Department, 75908, Paris, France aut Lefeuvre Sandrine Pharmacology Department, 75908, Paris, France aut Billaud Eliane Pharmacology Department, 75908, Paris, France aut Beaune Philippe Biochemistry Department, 75908, Paris, France aut Bobrie Guillaume Arterial Hypertension Department, 75908, Paris, France aut Azizi Michel INSERM, Clinical Investigation Center, 75908, Paris, France aut Prognon Patrice Pharmacy Department, 75908, Paris, France aut Laurent Stéphane Pharmacology Department, 75908, Paris, France aut Chromatographia Springer-Verlag 74/7-8(2011-10-01), 559-565 0009-5893 74:7-8<559 2011 74 10337 https://doi.org/10.1007/s10337-011-2111-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10337-011-2111-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Coudoré François Pharmacology Department, 75908, Paris, France aut NATIONALLICENCE 700 1- Harvard Laurent Pharmacy Department, 75908, Paris, France aut NATIONALLICENCE 700 1- Lefeuvre Sandrine Pharmacology Department, 75908, Paris, France aut NATIONALLICENCE 700 1- Billaud Eliane Pharmacology Department, 75908, Paris, France aut NATIONALLICENCE 700 1- Beaune Philippe Biochemistry Department, 75908, Paris, France aut NATIONALLICENCE 700 1- Bobrie Guillaume Arterial Hypertension Department, 75908, Paris, France aut NATIONALLICENCE 700 1- Azizi Michel INSERM, Clinical Investigation Center, 75908, Paris, France aut NATIONALLICENCE 700 1- Prognon Patrice Pharmacy Department, 75908, Paris, France aut NATIONALLICENCE 700 1- Laurent Stéphane Pharmacology Department, 75908, Paris, France aut NATIONALLICENCE 773 0- Chromatographia Springer-Verlag 74/7-8(2011-10-01), 559-565 0009-5893 74:7-8<559 2011 74 10337 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer